(December 21, 2015, 12:10 PM EST) -- HOUSTON — A Texas federal judge on Dec. 10 granted partial summary judgment to Solvay Pharmaceuticals Inc. (SPI) in a False Claims Act (FCA)/Anti-Kickback whistle-blower complaint alleging improper promotion of the blood pressure drug Aceon and the antidepressant drug Luvox (United States of America, ex rel. John King, et al. v. Solvay S.A., et al., No. 06-2662, S.D. Texas, Houston Div.; 2015 U.S. Dist. LEXIS 165792)....